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The host developing resistance to retroviral infection is believed to be a major force in the evolution of multiple receptor
usage by retroviruses. The avian leukosis–sarcoma virus (ALV) group of retroviruses provides a powerful system for studying
the envelope–receptor interactions involved in retrovirus entry; different members of this group of closely related viruses use
distinct cellular receptors. Analysis of the ALV envelope subgroups suggests that the different ALVs evolved from a common
ancestor by mutations in the env gene. Cells and animals that express subgroup A ALV envelope glycoproteins are highly
resistant to ALV(A) infection due to receptor interference. In this study, we tested whether expression of a soluble form of
subgroup A surface glycoprotein (SU) would result in receptor interference and whether this interference would select for
resistant viruses with altered receptor usage. Chicken cells expressing the secreted ALV(A) SU immunoadhesin SU(A)-rIgG,
which contains the subgroup A SU domain fused to the constant region of a rabbit immunoglobulin (IgG) heavy chain, showed
significant receptor interference. A variant virus resistant to SU(A)-rIgG receptor interference was obtained. This virus had
a six-amino-acid deletion in the subgroup A hr1 that altered receptor usage. This approach may identify regions of SU that
play a critical role in receptor specificity. © 2000 Academic PressINTRODUCTION
Retroviruses efficiently infect only those cells that ex-
press a specific receptor that can interact with the viral
envelope glycoproteins (Hunter, 1997). Resistance to ret-
rovirus infection can occur at the cell surface in two
ways: (i) genetic resistance, i.e., a version of the specific
receptor that can be recognized by the virus is not
present on the cell surface; and (ii) receptor interference,
i.e., the receptors are unavailable to retroviruses of the
same subgroup due to interaction with the viral envelope
glycoprotein in the secretory pathway and/or at the cell
surface that leads to the degradation of the complex
(Hunter, 1997; Weiss, 1982, 1992). The selective pressure
of the host developing resistance to retroviral infection
has been proposed as a major force in the evolution of
retroviruses to alter their receptor usage (Coffin, 1990,
1992). The avian leukosis–sarcoma virus (ALV) group of
retroviruses provides a powerful system for studying the
envelope–receptor interactions involved in retrovirus en-
try because different members of this group of closely
related viruses use distinct cellular receptors (Weiss,
1992). Analysis of the ALV envelope subgroups suggests
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364that the different ALVs evolved from a common ancestor
by mutations in the env gene.
ALVs have been divided into 10 envelope subgroups, A
through J, based on host range, receptor interference
patterns, and neutralization by antibodies (Weiss, 1992).
The subgroup A to E viruses have been divided into
noncytopathic (A, C, and E) and cytopathic (B and D)
groups; cytopathic ALVs can cause a transient cytotox-
icity in 30–40% of the infected cells (Weller et al., 1980;
Weller and Temin, 1981). Recently ALV replication in DF-1
cells, a permanent, nontransformed cell line derived from
Line 0 chicken embryo fibroblasts, was described (Himly
et al., 1998; Schaefer-Klein et al., 1998). Unexpectedly,
infection of DF-1 cells with subgroup C ALV caused a
transient cytotoxicity similar to the cytotoxicity observed
in avian cell cultures (including DF-1) infected with sub-
group B and D viruses. Three genetic loci determine the
susceptibility of chicken cells to the subgroup A to E
ALVs, tv-a, tv-b, and tv-c (Weiss, 1992). Susceptibility to
subgroup A ALV infection is controlled by tv-a, suscepti-
bility to subgroup C by tv-c, and susceptibility to sub-
groups B, D, and E by tv-b. The receptor for subgroup A
ALV, Tva, contains sequences related to the ligand-bind-
ing region of low-density lipoprotein receptors (Bates et
al., 1993, 1998; Young et al., 1993). The receptor for
subgroups B and D ALVs, CAR1, and the receptor for
subgroup E ALV, SEAR, are related to tumor necrosis
factor receptors (Adkins et al., 1997; Brojatsch et al.,
1996; Smith et al., 1998). The subgroup C receptor has
not yet been identified.
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365ALV(A) MUTANT RESISTANT TO SU(A)-rIgGThe mature ALV envelope glycoproteins are trimers
composed of the surface glycoprotein (SU) covalently
bound to the transmembrane glycoprotein (TM) (Hunter,
1997). The major domains that interact with the host cell
receptor are contained in SU while TM anchors SU to the
cell membrane and appears to be directly involved in the
fusion of the viral and cellular membranes. The subgroup
A to E envelope glycoproteins are homologous and
highly related (average 85% identity) except for five small
regions in SU (vr1, vr2, hr1, hr2, and vr3) (Fig. 1) (Bova et
al., 1986, 1988; Dorner et al., 1985). The results of several
studies characterizing viruses with recombinant env
genes suggest that the principal interactions between
SU and the receptor that determine which receptor is
recognized involve the hr1 and hr2 regions (Dorner and
Coffin, 1986; Tsichlis and Coffin, 1980; Tsichlis et al.,
1980). The vr3 region may play a role in receptor recog-
nition but does not appear to contribute to binding spec-
ificity; vr1 and vr2 do not appear to be necessary for
receptor specificity.
The selective pressure of host resistance has appar-
ently caused ALV to use alternative receptors. To test this
hypothesis, Taplitz and Coffin passaged a subgroup B
virus, td-Pr-RSV-B, on a mixture of permissive chicken
(C/E) and nonpermissive quail (QT6/BD) cells and se-
lected for variant viruses able to replicate in cells that
lacked the subgroup B receptor (Taplitz and Coffin, 1997).
A variant virus with an extended host range was identi-
fied that had two amino acid changes, L155S and T156I,
FIG. 1. (A) Schematic representations of the ALV-based RCASBP re
glycoproteins. The five regions of amino acid sequence variation (vr1,
glycoproteins (SU) of ALV subgroups A to E are also shown. (B) Compa
and hr2, of representative ALV envelope subgroups A to E. The sequen
6.5. Amino acids identical to SR-A are denoted by (F); gaps in the align
virus identified in this study and the homologous regions in subgroupin the hr1 region of SU (see Fig. 1B; the first two residues
of RAV-2 in the box). The variant virus was able to useboth the chicken subgroup B receptor and the quail
subgroup E receptor. These data showed that small
changes in the ALV envelope gene could alter receptor
usage to circumvent genetic resistance.
Cells and animals that express subgroup A ALV enve-
lope glycoproteins are highly resistant to superinfection
by ALV(A) (Crittenden et al., 1989; Federspiel et al., 1991;
Salter and Crittenden, 1989, 1991). We tested whether
expression of a soluble form of subgroup A SU would
cause receptor interference and select for resistant vi-
ruses with altered receptor usage. Chicken cells ex-
pressing the secreted ALV(A) SU immunoadhesin SU(A)-
rIgG, which contains the subgroup A SU domain fused to
the constant region of a rabbit immunoglobulin (IgG)
heavy chain (Zingler and Young, 1996), showed signifi-
cant resistance to ALV(A) infection. A variant virus resis-
tant to SU(A)-rIgG receptor interference that contained a
six-amino-acid deletion in the subgroup A hr1 was se-
lected; this deletion altered receptor usage.
RESULTS
SU(A)-rIgG significantly inhibits ALV(A) infection
Clonal cell lines expressing SU(A)-rIgG were produced
by calcium phosphate transfection of TFANEO/SU(A)-
rIgG plasmid DNA into DF-1 cells. DF-1 cells do not
contain endogenous sequences closely related to the
ALV-based vectors (Astrin et al., 1979), eliminating pos-
sible recombinants between the vector and endoge-
n-competent retroviral vector and the major domains of the envelope
1, hr2, and vr3) identified by comparing the sequences of the surface
f the amino acid sequences of the two major SU variable domains, hr1
re aligned with the ClustalW multiple alignment program of MacVector
re denoted by (2). The region in subgroup A hr1 deleted in the variant
are highlighted in a box.plicatio
vr2, hr
rison o
ces wenous viruses. To determine the level of resistance to
ALV(A) infection, the cell lines were challenged with
s
r
S
S
R
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366 HOLMEN AND FEDERSPIELRCASBP(A)AP. A range of resistance to infection by
RCASBP(A)AP (;1,000–185,000-fold) was produced by
the different cell lines (Table 1). The TF/SU(A)-19 cell line
produced the highest level of resistance to infection by
RCASBP(A)AP, ;185,000-fold, and the antiviral effect was
pecific for ALV(A) (Table 2), which is consistent with a
eceptor interference mechanism.
election of RCASBP(A) variants resistant to the
U(A)rIgG antiviral effect
TF/SU(A)-19 cells (3.5 3 106) were challenged with
CASBP(A)AP (titer 5.3 6 1.9 3 106 ifu/ml) at a multiplicity
of infection of 1.5, 3.0, or 7.6 ifu/cell. As a control, a cell
line transfected with the TFANEO plasmid alone was
challenged with either ;1 or ;10 ifu of RCASBP(A)AP to
monitor the rate of viral spread in the absence of SU-
(A)rIgG when the number of cells initially infected was
low. The infected cell lines were passaged and moni-
tored for virus production by assaying for the ALV CA
protein by ELISA. ALV CA protein levels rose rapidly in
the control cultures and reached peak levels 8–12 days
postinfection (Fig. 2A). In the infected TF/SU(A)-19 cul-
tures virus replication was seen only after infection at 7.6
ifu/cell: detectable levels of ALV CA were produced 20
days postinfection and peak levels were seen by day 32
(Fig. 2A). We observed a transient cytotoxicity in the
infected TF/SU(A)-19 culture 32 days postinfection which
lasted several days. The observed cytotoxicity was sim-
ilar to the transient cytotoxicity previously observed in
DF-1 cultures infected with either RCASBP(B) or
RCASBP(C) viruses. All cultures were negative for sub-
group B and C ALVs as assayed by PCR with subgroup-
specific primers (data not shown).
To determine whether we had selected a viral popu-
lation that replicates more efficiently in TF/SU(A)-19 cells
TABLE 1
Relative Resistance of DF-1 Cell Lines Expressing SU(A)-rIgG
to ALV(A) Infection
Cell line RCASBP(A)AP titera Resistanceb
Uninfected DF-1 4.5 3 106 —
TFANEO alone 2.9 3 106 1.5
TF/SU(A)-4 1.2 3 103 4090
TF/SU(A)-7 2.2 3 103 2045
TF/SU(A)-9 4.6 3 103 978
TF/SU(A)-19 2.4 3 101 187,500
TF/SU(A)-23 1.3 3 102 36,000
TF/SU(A)-30 1.5 3 103 3000
a The titer (ifu/ml) is the average of duplicate assays.
b The resistance of cells to ALV(A) infection was determined by
dividing the average titer obtained on the control uninfected DF-1 cells
by the average titer obtained for each experimental cell line.than wild-type RCASBP(A)AP, uninfected TF/SU(A)-19
cells were challenged with 5 ml of day-36 supernatant
d
mfrom either the infected TF/SU(A)-19 culture or a control
culture. The cultures were passaged and monitored for
virus production by ELISA. The virus produced by the
TF/SU(A)-19 culture (Fig. 2A) replicated better than wild-
type RCASBP(A)AP in TF/SU(A)-19 cells (Fig. 2B).
The selected viruses contain a six-amino-acid
deletion within the hr1 region of SU
The 1.1-kb SU region of the env gene was amplified by
PCR from genomic DNA isolated from the day-20 TF/
SU(A)-19 culture (Fig. 2B). The SU regions were amplified
in two separate reactions, one using Taq DNA polymer-
ase and one using Vent polymerase to control for any
changes that might have been introduced by the PCR.
The amplified products were cloned and the nucleotide
sequence of SU was compiled from 22 clones. The
deduced amino acid sequence of each clone was com-
pared to the SU sequence of the parental virus
RCASBP(A). All of the SU regions cloned from the TF/
SU(A)-19 culture contained a deletion of amino acids
155–160 (D155–160) in hr1 (Fig. 3). Several clones con-
tained additional amino acid differences in SU compared
to RCASBP(A).
A RCASBP(A)AP molecular clone with the
SU D155–160 mutation is resistant to the
antiviral effect of SU(A)-rIgG
To determine whether the D155–160 mutation provided
a growth advantage in cells expressing SU(A)-rIgG, we
replaced the SU fragment in the wild-type RCASBP(A)AP
molecular clone with the SU fragment containing the
D155–160 mutation. Wild-type and mutant RCASBP(A)AP
plasmid DNAs were transfected into both DF-1 and TF/
SU(A)-19 cells. To determine the rate of viral spread in
each culture, the culture supernatants were assayed for
infectious virus on DF-1 cells by AP assay. The D155–160
mutant virus produced infectious virus in DF-1 cells at a
somewhat slower rate and to a 10- to 20-fold lower titer
compared to wild-type RCASBP(A)AP (Fig. 4). In addition,
a transient period of cytotoxicity was observed 12 to 16
days posttransfection in the D155–160 virus-infected
TABLE 2
Relative Resistance of TF/SU(A)-19 Cells to ALV Infection
Virus
Titer (mean 6 SD)
ResistanceaDF-1 TF/SU(A)-19
RCASBP(A)AP 5.3 6 1.9 3 106 2.9 6 3.2 3 101 182,700
CASBP(B)AP 1.4 6 0.1 3 105 1.0 6 0.5 3 105 1.4
RCASBP(C)AP 3.0 6 1.3 3 105 8.8 6 1.5 3 104 3.4
a The resistance of the TF/SU(A)-19 cells to virus infection was
etermined by dividing the mean titer obtained in the DF-1 cells by the
ean titer obtained for each virus in TF/SU(A)-19 cells.
5.0 ml o
367ALV(A) MUTANT RESISTANT TO SU(A)-rIgGDF-1 culture, after which the cells recovered. The D155–
160 mutant virus did not replicate as well in TF/SU(A)-19
cells as in DF-1 cells; the titer in TF/SU(A)-19 cells was 5-
FIG. 2. Selection of variant subgroup A ALVs resistant to SU(A)-rIgG
transfected with the TFANEO/SU(A)-rIgG plasmid and expressing SU(A)
of 7.6 (h), 3.0 ({), or 1.5 (E) ifu/cell. As controls, the TFANEO control DF
growth was monitored by ELISA for the ALV CA protein. The arrow
TF/SU(A)-19 culture. (B) Uninfected TF/SU(A)-19 cells were infected with
culture ( n ) (see A). Viral growth was monitored by ELISA.
FIG. 3. Identification of a variant subgroup A virus. The SU regions
from the TF/SU(A)-19 infected culture. The genes were amplified by P
determined. A schematic of the cloned region is included at the top. T
(gp85). The amino acids contained in the five variable regions are: vr1
amino acid sequences of the hr1 and hr2 region of each SU clone com
Taq DNA polymerase; clones 13–22 were amplified by Vent DNA polym
are shown. Deletions in the alignment are denoted by (2). A stop codon is des
are also listed.to 10-fold lower (Fig. 4). A transient period of cytotoxicity
was also observed 24 to 28 days posttransfection in the
D155–160 virus infected TF/SU(A)-19 cells. The TF/
r interference. (A) TF/SU(A)-19 cells, a cell line derived from DF-1 cells
rotein, were challenged with RCASBP(A)AP at a multiplicity of infection
line was challenged with ;1 ifu (F) or ;10 ifu (n ) RCASBP(A)AP. Viral
ate the period of transient cytotoxicity observed in the challenged
f day-36 supernatant from the TF/SU(A)-19 culture (h) or from a control
nv genes of ALV proviruses were cloned from genomic DNA isolated
cloned as KpnI to SalI fragments, and the nucleotide sequence was
ino acids are numbered from the start of the mature SU glycoprotein
vr2 100–105; hr1 122–165; hr2 199–227; and vr3 261–269. The deduced
to the wild-type sequence are shown. Clones 1–12 were amplified by
. The differences in amino acid sequence compared to SR-A SU (WT)recepto
-rIgG p
-1 cell
s indicof the e
CR and
he am
64–75;
pared
eraseignated by (*). Any additional amino acid changes found in each clone
368 HOLMEN AND FEDERSPIELSU(A)-19 cells transfected with wild-type RCASBP(A)AP
DNA failed to produce detectable levels of infectious
wild-type virus (Fig. 4).
Analysis of receptor interference patterns
To determine whether the mutant D155–160 envelope
glycoproteins altered the receptor usage of D155–160
RCASBP(A)AP, we performed a series of receptor inter-
FIG. 4. Replication of recombinant RCASBP(A)AP containing the
D155–160 mutation. Plasmid DNAs containing the wild-type
RCASBP(A)AP virus (open symbols) or a recombinant RCASBP(A)AP
containing the D155–160 mutation (closed symbols) in proviral form
were transfected into DF-1 (h or n ) or TF/SU(A)-19 (E or F). Virus
growth was monitored by determining the infectious titer produced by
each culture by AP assay. The arrows define the period of cytotoxicity
observed in the DF-1 and TF/SU(A)-19 cultures.
FIG. 5. Analysis of the receptor interference patterns of the D155–16
D155–160 mutant in TF/SU(A)-19 cells. Uninfected DF-1 cells (DF-1) and
(C), or subgroup J HPRS-103 (J) were infected with 10-fold serial dilutions of the
was quantitated by AP assay. The results shown are an average of three diffference assays. Uninfected DF-1 cells and DF-1 cells
chronically infected with ALVs of subgroup A
[RCASBP(A)], subgroup B [RCASBP(B)], subgroup C,
[RCASBP(C)], or subgroup J (pHPRS103) were challenged
with 10-fold serial dilutions of either the wild-type
RCASBP(A)AP virus or the D155–160 mutant and the viral
titer was determined by AP assay. Uninfected DF-1 cells
and DF-1 cells infected with subgroups B, C, and J ALVs
were efficiently infected by RCASBP(A)AP (Fig. 5). How-
ever, in DF-1 cells infected with subgroup A ALV,
RCASBP(A)AP infection was inhibited by 5 logs (Fig. 5)
and superinfection of subgroup B infected cells with
RCASBP(B)AP or subgroup C infected cells with
RCASBP(C)AP produced a 4-log decrease in titer (data
not shown). The receptor interference profiles of the
D155–160 RCASBP(A)AP mutant virus propagated in
DF-1 cells and TF/SU(A)-19 cells were very similar (Fig.
5). The D155–160 mutant virus infected the subgroup A
infected DF-1 cells much more efficiently (within 10-fold
of the titer on DF-1 cells) compared to wild-type
RCASBP(A)AP. The D155–160 mutant virus was some-
what less efficient at infecting cells previously infected
with subgroups B and C ALVs compared to wild-type (5-
to 10-fold) which may indicate that the D155–160 virus
can use the Tvb and Tvc receptors to enter cells.
The D155–160 mutant envelope glycoproteins can still
interact with Tva
To determine whether the deletion in the hr1 region in
the D155–160 mutant resulted in a lower binding affinity
for the Tva receptor, the D155–160 and wild-type
nt and wild-type RCASBP(A)AP viruses produced in DF-1 cells and the
lls chronically infected with RCASBP(A) (A), RCASBP(B) (B), RCASBP(C)0 muta
DF-1 ceculture supernatants collected 20 days after transfection and the titer
erent experiments.
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369ALV(A) MUTANT RESISTANT TO SU(A)-rIgGRCASBP(A)AP envelope glycoproteins were assayed for
sTva-mIgG binding by FACS. The sTva-mIgG protein is a
soluble form of the quail Tva extracellular domain fused
to a mouse immunoglobulin G heavy chain (Holmen et
al., 1999). The fluorescence on the cell surface was
plotted against the sTva-mIgG concentration (Fig. 6). The
envelope glycoproteins expressed on cells infected with
the D155–160 mutant bound sTva-mIgG at approximately
60% of the level bound by cells infected by wild-type virus
(Fig. 6). The dissociation constant (K D) was determined
y a linear least squares fit to a double reciprocal plot
Lineweaver–Burk); K D 5 21/x-intercept (Yu et al., 1995).
There was no significant difference in the K D of sTva-
mIgG binding to the wild-type and D155–160 mutant
envelope glycoproteins (KD 5 ;1 nM) indicating that the
155–160 mutation does not affect the binding affinity of
he envelope glycoprotein for sTva-mIgG at 4°C (data not
hown).
The antiviral effect of sTva-mIgG on wild-type and
utant virions was also determined as a measure of the
nteraction of the wild-type and D155–160 mutant glyco-
roteins with Tva. We have recently shown that sTva-
IgG significantly inhibited ALV(A) infection in cells and
hickens expressing sTva-mIgG (Holmen et al., 1999).
irions collected from the DF-1 cultures infected with
155–160 or wild-type RCASBP(A)AP were preabsorbed
ith sTva-mIgG and the infectious titer determined on
F/sTvaI-4 cells, a DF-1 cell line that expresses sTva-
IgG (Holmen et al., 1999). Treatment of wild-type
CASBP(A)AP virus with sTva-mIgG in this assay re-
uced the titer ;15,600-fold compared to untreated virus
FIG. 6. The binding affinity of the D155–160 mutant envelope glycopro-
teins for sTva-mIgG. DF-1 cells infected with the D155–160 recombinant
(n ) or wild-type (}) RCASBP(A)AP viruses (see Fig. 4) were fixed and
ncubated with different amounts of sTva-mIgG protein and the envelope
lycoprotein:sTva-mIgG complexes bound to sheep anti-mouse Ig anti-
ody linked to fluorescein. The levels of fluorescein bound to the infected
ells were quantitated by FACS and the mean level of fluorescence was
lotted as a function of sTva-mIgG concentration. The values shown are
n average of three different experiments.Table 3). sTva-mIgG preabsorption of D155–160 mutant
irions reduced the titer ;550-fold indicating a reducedffinity of the envelope glycoproteins for sTva-mIgG. One
ossible explanation for the apparent difference in bind-
ng affinity of the D155–160 envelope glycoprotein for
Tva-mIgG in the two assays may be the binding tem-
erature. While sTva-mIgG was bound to the envelope
lycoproteins at 4°C in both the FACS binding assay and
he antiviral assay, the antiviral effect was measured by
nfecting DF-1 cells at 39°C which may alter virion/sTva-
IgG binding. Therefore, the D155–160 mutant envelope
lycoproteins may have a lower binding affinity for sTva-
IgG at higher temperatures.
To determine whether the D155–160 mutant virus
ould efficiently infect cells using the Tva receptor,
155–160 mutant and wild-type RCASBP(A)AP DF-1 virus
tocks were titered on chicken DF-1 cells (C/E), quail
T6 cells (QT6/BD), mouse NIH 3T3 cells, and NIH3T3
ells that express the quail pg950 Tva receptor
3T3pg950). QT6 express the quail Tva receptor. NIH3T3
ells are not efficiently infected by ALV because they lack
unctional receptors. As expected, the D155–160 mutant
nd wild-type RCASBP(A)AP viruses did not infect
IH3T3 cells (data not shown). The D155–160 mutant
irus efficiently infected all three cell lines expressing
hicken or quail Tva, including 3T3pg950 cells which
xpress only the Tva receptor (Fig. 7). The titers of the
155–160 virus, which were 5- to 8-fold lower than wild-
ype, were expected to be lower since the virus repli-
ates to a lower titer in DF-1 cells compared to wild-type
see Fig. 4). While the results of the antiviral assay
ndicate that the D155–160 mutant envelope glycopro-
eins may have a reduced binding affinity for sTva-mIgG,
he D155–160 mutant virus can still efficiently infect cells
hat express only the Tva receptor.
TABLE 3
Relative Resistance of TF/sTvaI-4 Cells to Infection by D155–160
Mutant and Wild-Type RCASBP(A)AP Viruses
Virus
(cell type)
Titer (mean 6 SD)
ResistancebDF-1 TF/sTvaI-4a
Wild-type
(DF-1)
5.3 6 1.9 3 106 3.4 6 1.2 3 102 15,588
155–160
(DF-1)
2.5 6 0.4 3 105 4.5 6 0.2 3 102 555 (28)
155–160
(TF/SUA-19)
4.4 6 1.3 3 104 7.9 6 1.0 3 101 556 (28)
a Virions were preabsorbed with supernatant from a confluent TF/
TvaI-4 culture containing the sTva-mIgG protein prior to assay.
b The resistance of the TF/sTvaI-4 cells to virus infection was deter-
mined by dividing the mean titer obtained in the DF-1 cells by the mean
titer obtained for each virus in TF/sTvaI-4 cells. The fold difference in
the resistance of the mutant virus compared to wild-type virus is given
in parentheses.
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370 HOLMEN AND FEDERSPIELDISCUSSION
We believe that the SU(A)-rIgG protein blocks the ac-
ess of ALV(A) to the Tva receptor by the same mecha-
ism(s) as the membrane-bound envelope glycoprotein:
direct interaction with the Tva receptor, at the cell
urface and/or intracellularly in the secretory pathway,
hat leads to receptor degradation. Therefore, we hypoth-
sized that variant subgroup A ALVs resistant to the
ntiviral effect of SU(A)-rIgG would have mutations in the
nvelope glycoprotein and would use an alternate recep-
or. As we predicted, a variant ALV(A) resistant to SU(A)-
IgG contained a mutation in the envelope glycoprotein
hat altered receptor usage. However, despite the dele-
ion of six amino acid residues in the subgroup A hr1, the
155–160 virus was still able to use the Tva receptor to
fficiently infect cells. The D155–160 mutation was in the
-terminal end of the subgroup A hr1 domain (Figs. 1B
nd 3). In the study of Taplitz and Coffin, genetic resis-
ance was used to select a subgroup B ALV variant
apable of infecting cells using the subgroup E receptor.
he ALV(B) variant contained two amino acid changes in
he region of the subgroup B hr1 domain homologous to
he D155–160 mutation (Fig. 1B; see box). This same
egion of the hr1 domain contains amino acid insertions
n the other ALV subgroups, two residues in subgroup C,
nd seven residues in subgroups B, D, and E, relative to
ubgroup A hr1 (Fig. 1B; see box). These data may
ndicate that this region of hr1 plays a critical role in
eceptor specificity.
The deletion of residues 155–160 of subgroup A hr1
FIG. 7. Analysis of the ability of the D155–160 mutant virus to use the
va receptor. DF-1 cells (chicken Tva), QT6 cells (quail Tva), and
T3pg950 cells (NIH3T3 cells expressing the quail pg950 Tva) were
nfected with 10-fold serial dilutions of the D155–160 mutant (u) or
ild-type ( n ) RCASBP(A)AP DF-1 virus stocks and the viral titer was
uantitated by AP assay. The results shown are an average of three
ifferent experiments.ay have changed the structure of the surface glycop-
otein such that virions produced with the D155–160utant envelope glycoproteins may be capable of infect-
ng cells by interacting with other cell surface protein(s)
n addition to Tva. Since the different ALV envelope sub-
roups may have evolved from a common ancestor be-
ause of host resistance, one possibility is that the
155–160 mutant can also use a different ALV receptor.
e do not have conclusive data; however, the D155–160
utant RCASBP(A)AP, RCASBP(B)AP, and RCASBP(C)AP
iruses all replicate to similar titers and induce cytotox-
city in DF-1 cells. In addition, the receptor interference
nalysis showed that the D155–160 virus did not infect
ells already infected with subgroup B or C ALV as
fficiently as wild-type. Taken together, the D155–160
irus may use the Tvb and/or Tvc receptors, at least in
art, to infect DF-1 cells. However, the D155–160 RCASB-
P(A)AP mutant virus did not show an altered receptor
interference pattern for the subgroup J ALV receptor
suggesting that it does not recognize this receptor.
These data suggest that the subgroup A to E ALVs
may share a common link in virus entry. A link between
the Tva, Tvb, and Tvc receptors, which excludes the
subgroup J receptor, could explain the observation that
the subgroup A to E ALV envelope glycoproteins are
homologous and highly related, while the subgroup J ALV
envelope glycoprotein is very different (e.g., ;44% iden-
tity with subgroup A). A possible link between these
receptors could be explained by a common structural
motif that is shared by these apparently very different
proteins. It should be kept in mind that the Tva and Tvb
receptors show no sequence relatedness and have no
known common structural features. Another possible link
could be a common accessory protein or coreceptor that
is required for efficient virus entry. This would be similar
to the situation in the entry of HIV-1 into susceptible
cells. In this model, viral envelopes that recognize Tva,
Tvb, and Tvc would also recognize the same or homol-
ogous coreceptor while a different coreceptor would be
required for efficient ALV(J) infection. If this idea is cor-
rect, the putative coreceptor must be evolutionarily con-
served and must also be expressed in a variety of spe-
cies since the expression of the Tva and Tvb receptors in
mammalian cells confers susceptibility to ALV infection.
MATERIALS AND METHODS
Envelope glycoprotein sequence alignment
The deduced amino acid sequences of the SU regions
of subgroup A to E ALVs were compared using the
ClustalW multiple sequence alignment program of
MacVector 6.5 (Oxford Molecular Ltd., Oxford, England).
The Schmidt-Ruppin subgroup A strain of Rous sarcoma
virus (SR-A, GenBank Accession No. M14901), Prague
subgroup C strain of Rous sarcoma virus (PR-C, Gen-
Bank Accession No. J02342), Rous associated virus type
2 (RAV-2, GenBank Accession No. M14902), Schmidt-
Ruppin subgroup D strain of Rous sarcoma virus (SR-D,
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371ALV(A) MUTANT RESISTANT TO SU(A)-rIgGGenBank Accession No. D10652), and Rous associated
virus type 0 (RAV-0, GenBank Accession No. M12171)
were used in the sequence alignments.
Vector constructions
The construction of the SU(A)-rIgG gene contained in
the plasmid pKZ387 was described previously (Zingler
and Young, 1996). The SU(A)-rIgG gene encodes the first
338 amino acids of the SR-A env gene fused to amino
acids 96 to 323 of the constant region of the rabbit
immunoglobulin G gene (GenBank Accession No.
K00752). The SU(A)-rIgG coding region was subcloned
into the NcoI and PstI sites of the adaptor plasmid
CLA12NCO (Federspiel and Hughes, 1997). The SU(A)-
rIgG gene was isolated as a ClaI fragment from
CLA12NCO and subcloned into the TFANEO expression
plasmid [TFANEO/SU(A)-rIgG]. The TFANEO expression
cassette consists of two LTRs derived from the RCAS
vector that provide a strong promoter, enhancer, and
polyadenylation sites flanking a unique ClaI insertion site
(Federspiel et al., 1989). The TFANEO plasmid also con-
tains a neo resistance gene expressed under the control
of the chicken b-actin promoter and an ampicillin resis-
tance gene for selection in Escherichia coli.
The construction of the RCASBP(A)AP retroviral vector,
an ALV-based replication competent vector with a sub-
group A env gene, and the heat stable human placental
alkaline phosphatase gene (AP) has been described
(Federspiel and Hughes, 1997; Fekete and Cepko, 1993;
Fields-Berry et al., 1992). The SalI sites flanking the AP
gene were made blunt with the Klenow fragment of DNA
polymerase type I (New England Biolabs, Beverly, MA),
and the modified fragment was cloned into the SalI site
(also made blunt) of the CLA12 adaptor plasmid. The
APSal- gene was subcloned into the RCASBP(A) vector as
ClaI fragment to produce RCASBP(A)APSal-. The region
encoding the D155–160 mutant SU was isolated on a
Asp718 to SalI fragment from the pBluescript KS clone 20
(see Fig. 3) and cloned into the unique Asp718 and SalI
sites of the RCASBP(A)APSal- vector. The mutation in the
env gene of the recombinant RCASBP(A)APSal- clones
as verified by nucleotide sequence analysis.
ell culture and virus propagation
DF-1 cells (Himly et al., 1998; Schaefer-Klein et al.,
998) and QT6 cells (Moscovici et al., 1977) were grown
in Dulbecco’s modified Eagle’s medium (Gibco/BRL) sup-
plemented with 10% fetal bovine serum (Gibco/BRL), 100
units of penicillin/ml, and 100 mg of streptomycin/ml
(Quality Biological, Inc, Gaithersburg, MD) at 39°C and
5% CO2. The generation of the 3T3pg950 cell line, a
NIH3T3 cell line expressing the quail pg950 Tva receptor,
was previously described (Gilbert et al., 1994). The
3T3pg950 cells were grown in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% calf serum (Gibco/
;
aBRL), 250 mg of G418/ml (Gibco/BRL), 100 units of peni-
cillin/ml, and 100 mg of streptomycin/ml at 37°C and 5%
CO2. The cultures were passaged 1:3 or 1:6 when con-
luent.
Virus propagation was initiated either by transfection
f plasmid DNA that contained the retroviral vector in
roviral form (Federspiel and Hughes, 1997) or by direct
nfection. In standard transfections, 5 mg of purified plas-
id DNA was introduced into DF-1 cells by the calcium
hosphate precipitation method (Kingston et al., 1989).
iral spread was monitored by assaying culture super-
atants for ALV capsid protein (CA) by ELISA (Smith et
l., 1979). Virus stocks were generated from cell super-
atants. The supernatants were cleared of cellular debris
y centrifugation at 2000g for 10 min at 4°C and stored in
liquots at 280°C. DF-1 cells transfected with the TFA-
EO plasmid were grown in 500 mg G418/ml to select for
neomycin-resistant cells. Clones were isolated using
cloning cylinders (Bellco Glass Inc., Vineland, NJ), ex-
panded, and maintained with standard medium supple-
mented with 250 mg/ml G418.
DF-1 cell cultures were chronically infected with
RCASBP(A), RCASBP(B), RCASBP(C), or HPRS-103. The
RCASBP viruses with subgroup (A), (B), and (C) env
genes have been described previously (Federspiel and
Hughes, 1997). HPRS-103 (GenBank Accession No.
Z46390) is an ALV with a subgroup J env gene (Bai et al.,
1995) and was obtained from Michael A. Skinner (Insti-
tute for Animal Health, Compton, Near Newbury, Berk-
shire, UK).
ELISA
The ALV CA protein was detected in culture superna-
tants by ELISA as previously described (Smith et al.,
1979). The level of sTva-mIgG was quantitated in culture
supernatants by ELISA for the mouse IgG tag as previ-
ously described (Holmen et al., 1999).
Cloning and nucleotide sequence analysis of
integrated viral DNA
DNA was isolated from cells in culture using the
QIAamp Tissue Kit (Qiagen). The SU region of the env
gene was amplified by PCR using either Taq DNA poly-
merase (Promega, Madison, WI) or Vent DNA polymer-
ase (New England Biolabs) with the primers 59-GGGAC-
GAGGTTATGCCGCTG-39 (;50 bp upstream of Asp718
site) and 59-ATGAGGAAAATTGCGGGTGG-39 (down-
stream of the SalI site). Each Taq PCR contained 1.25 ml
of 103 PCR buffer (final concentration, 50 mm Tris–Cl,
pH 8.3, 50 mM KCI, 7 mM MgCl2, 1.1 mM b-mercapto-
thanol), 1.25 ml of 1.7 mg/ml BSA, 0.5 ml of each dNTP at
5 mM, 0.5 ml of each primer (A260 5 5), 6.0 ml H2O, and
.0 ml of DNA (genomic DNA ;100 ng/ml; plasmid DNA2 ng/ml). The reactions were heated to 90°C for 1 min
nd initiated by the addition of 1.5 ml of Taq DNA poly-
b
t
o
w
a
D
p
H
d
p
3
S
a
p
372 HOLMEN AND FEDERSPIELmerase diluted 1:10 v/v (0.75 units). Thirty cycles of PCR
were carried out as follows: 90°C for 40 s, then 59°C for
80 s. Each Vent PCR contained 1.25 ml 103 Vent Pol
uffer and 0.125 ml of 1003 acetylated BSA (supplied by
he manufacturer), 1.0 ml of each dNTP at 25 mM, 0.5 ml
f each primer (A260 5 5), 0.625 ml of 0.1 M MgSO4, 6.0
ml H2), 1.0 ml 50% DMSO, and 1.0 ml of DNA (genomic
DNA ;100 ng/ml; plasmid DNA ;2 ng/ml). The reactions
ere heated to 90°C for 1 min and initiated by the
ddition of 0.5 ml of Vent DNA polymerase diluted 1:2 v/v
(0.5 units). Thirty cycles of PCR were carried out as
follows: 90°C for 40 s, then 59°C for 80 s.
The amplified products were separated by agarose gel
electrophoresis and the 1.1-kb product was purified and
digested with Asp718 and SalI. The digested product was
cloned into pBluescript KS (Stratagene, LaJolla, CA) di-
gested with Asp718 and SalI. The nucleotide sequence of
the SU region was determined by the Mayo Clinic Mo-
lecular Biology Core on a Perkin–Elmer ABI PRISM 377
DNA sequencer (with XL upgrade) with PE Applied Bio-
systems ABI PRISM dRhodamine terminator cycle se-
quencing ready reaction kit and AmpliTaq DNA polymer-
ase (PE Applied Biosystems, Foster City, CA).
ALV alkaline phosphatase challenge assay
DF-1 cell cultures (;30% confluent) were incubated
with 10-fold serial dilutions of the RCASBP/AP virus
stocks for 36–48 h at 39°C. In a preabsorption AP chal-
lenge assay, the 10-fold viral serial dilutions were first
mixed with 2 ml of supernatant containing sTva-mIgG for
3 h at 4°C and then assayed as above. The assay for
alkaline phosphatase activity was described previously
(Holmen et al., 1999). The RCASBP(A)AP, RCASBP(B)AP,
and RCASBP(C)AP retroviral vectors which contain the
AP gene have been described previously (Federspiel and
Hughes, 1997).
Fluorescence-activated cell sorting (FACS) analysis of
envelope glycoprotein binding to sTva-mIgG
Uninfected DF-1 cells or DF-1 cells infected with either
wild-type or D155–160 mutant RCASBP(A)AP virus were
removed from culture dishes with Trypsin de Larco
(Quality Biological, Inc.) and washed with Dulbecco’s
phosphate-buffered saline. The cells were fixed with 4%
paraformaldehyde in PBS at room temperature for 15
min. Approximately 1 3 106 cells in PBS supplemented
with 1% calf serum (PBS-CS) were incubated with super-
natant containing sTva-mIgG (1 ml total volume) on ice
for 30 min. The cells were then washed with PBS-CS and
incubated with 5 ml of sheep anti-mouse Ig linked to
fluorescein (Amersham Pharmacia Biotech, Arlington
Heights, IL) in PBS-CS (1 ml total volume) on ice for 30
min. The cell:sTva-mIgG:Ig-fluorescein complexes were
washed with PBS-CS, resuspended in 0.5 ml PBS-CS,and analyzed with a Becton–Dickinson FACSCalibur us-
ing CELLQuest 3.1 software.
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